Medicine and Dentistry
Pediatrics
100%
Chronic Kidney Disease
92%
Congestive Heart Failure
55%
Kidney Function
55%
Hazard Ratio
49%
Biological Marker
37%
Acute Kidney Injury
36%
Pediatric Nephrology
32%
Odds Ratio
31%
Glomerular Filtration Rate
30%
Cardiovascular Disease
28%
Diuretics
27%
Brain Natriuretic Peptide
26%
Cohort Analysis
25%
Cardiovascular System
24%
Decompensated Heart Failure
23%
Acute Decompensated Heart Failure
23%
Outpatient
19%
Diseases
19%
Sodium Glucose Cotransporter 2 Inhibitor
18%
Creatinine
17%
Awareness
17%
Diuresis
16%
Mild Hepatic Impairment
16%
Loop Diuretic Agent
16%
Intensive Care
16%
Graft Survival
16%
Racial Group
16%
Ethnic Groups
16%
Blood Pressure Reduction
16%
ECG Abnormality
16%
Disease Exacerbation
16%
Retrospective Cohort Study
16%
Intensive Care Unit
16%
Neonatal Intensive Care Unit
16%
Heart Left Ventricle Failure
16%
Blood Urea Nitrogen
16%
COVID-19 Vaccination
16%
Kidney Graft
16%
Titrimetry
16%
Cardiorenal Syndrome
16%
Nephrology
15%
Infection
13%
Severe Acute Respiratory Syndrome Coronavirus 2
13%
Alanine Aminotransferase
12%
Bilirubin
12%
Urine Sampling
12%
Blood Pressure Monitoring
12%
Retransplantation
10%
Heart Transplantation
10%
Keyphrases
Chronic Kidney Disease
88%
Confidence Interval
54%
Renal Disease
49%
Older Adults
41%
Acute Kidney Injury
36%
Cardiac Biomarkers
32%
Pediatric Nephrology
32%
Pediatric Chronic Kidney Disease
32%
Acute Decompensated Heart Failure
30%
Pediatric
27%
Renal Function Improvement
25%
Heart Failure
23%
Odds Ratio
23%
Cardiovascular Disease
23%
Living with
21%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
21%
Cardiovascular Events
20%
Knowledge Gaps
20%
Hazard Ratio
20%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
19%
Type 2 Diabetes Mellitus (T2DM)
19%
Kidney Disease Progression
18%
Hypertension
18%
Cardiovascular Risk
17%
Patients with Heart Failure
16%
Research Consortium
16%
Safety Outcomes
16%
Left Ventricular Dysfunction
16%
Allograft Survival
16%
Electrocardiographic Abnormalities
16%
Loop Diuretics
16%
Enhanced Awareness
16%
Cardiac Allograft
16%
Ethnic Groups
16%
COVID-19 Vaccination
16%
Influence of Age
16%
Age-related
16%
Racial Groups
16%
Mortality Burden
16%
Reporting Results
16%
Nephrology Research
16%
Reversible Renal Dysfunction
16%
Injury Reports
16%
Major Adverse Kidney Events
16%
Infectious Outcomes
16%
Fully Vaccinated
16%
Pediatric Kidney Transplant Recipients
16%
Years of Life Lost
16%
Pediatric CKD
16%
Retrospective Cohort Study
16%
